


Product Name : AZD8421
Cat. No. : PC-22118
CAS No. : 3047321-53-6
Molecular Formula : C₁₈H₃₂N₈O₃S
Molecular Weight : 440.57
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



Biological Activity

AZD8421 (AZD-8421) is a potent, highly selective **CDK2** inhibitor with IC₅₀ of 9 nM, >300-fold selectivity over CDK9. AZD8421 forms hydrogen bonding interaction with Lys89 (a CDK2-specific residue) near the solvent region of the ATP-binding pocket.

AZD8421 displays high selectivity over CDK1, CDK4 and CDK6.

AZD8421 potentially inhibits cell proliferation (69 nM, OVCAR3), correlated with inhibition of pRB, arrest in G1/S phase of the cell cycle and induction of senescence, in a CCNE1 amplified cell line.

AZD8421 shows combination benefit when combined with approved CDK4/6 inhibitors in CDK4/6 inhibitor resistant breast cancer cell lines.

AZD8421 potentially suppresses phosphorylation of Rb, and demonstrates robust monotherapy and CDK4/6i combination activity in breast and ovarian in vivo models.

AZD8421 shows robust monotherapy activity in a CCNE1 amplified ovarian model OVCAR3 with regressions seen with monotherapy and in combination with palbociclib in CDK4/6 inhibitor resistant breast PDXs.

References

Christopher R. Denz, et al. **Cancer Res** (2024) 84 (7_Supplement): ND06.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com